Old Web
English
Sign In
Acemap
>
authorDetail
>
Justin L. Ricker
Justin L. Ricker
Celgene
Refractory
Oncology
Rituximab
Lenalidomide
Internal medicine
3
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
2018
Journal of Clinical Oncology
David J. Andorsky
Morton Coleman
Abdulraheem Yacoub
Jason M. Melear
Heather Dawn Brooks
Suzanne R. Fanning
Kathryn S. Kolibaba
Frederick Lansigan
C.K. Reynolds
Jiahui Li
Dongfang Liu
Mary Llorente
Justin L. Ricker
Jeff Porter Sharman
Show All
Source
Cite
Save
Citations (6)
PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA
2017
Hematological Oncology
Morton Coleman
David J. Andorsky
Abdulraheem Yacoub
Jason M. Melear
Kathryn S. Kolibaba
Heather Dawn Brooks
Jacob D. Bitran
Suzanne R. Fanning
Frederick Lansigan
Justin L. Ricker
Kenneth A. Foon
Mary Llorente
Jiahui Li
Jeffrey P. Sharman
Show All
Source
Cite
Save
Citations (4)
1